title: [Effect of antioxidant use in dietary therapy in patients with chronic athrofic hastritis].
abstract: In the 1-year double-blind placebo-controlled intervention trial, it was shown that daily supplementation of patients with gastric premalignant lesions (intestinal metaplasia, IM) with a complex, containing Ester-C with antioxidantsand (2100 mg of Ca-ascorbate + 340 mg of bioflavonoids), produced a sharp decrease of abnormally high ornithine decarboxylase activity in IM gastric mucosa that was accom panied by practically total IM regression in 11 of 18 (61%) patients.
authors.forename: V A
authors.initials: VA
authors.lastname: Draudin-Krylenko
authors.forename: A B
authors.initials: AB
authors.lastname: Petukhov
authors.forename: Iu P
authors.initials: IuP
authors.lastname: Kuvshinov
authors.forename: A A
authors.initials: AA
authors.lastname: Levchuk
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Bukin
mesh_terms: D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000008:administration & dosage*; D001205:Ascorbic Acid / Q000008:administration & dosage*; D002908:Chronic Disease; D004311:Double-Blind Method; D005260:Female; D005753:Gastric Mucosa / Q000201:enzymology / Q000382:microbiology / Q000473:pathology; D005757:Gastritis, Atrophic / Q000178:diet therapy* / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D016481:Helicobacter Infections / Q000178:diet therapy* / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D007422:Intestines / Q000201:enzymology / Q000473:pathology; D008297:Male; D008679:Metaplasia / Q000178:diet therapy / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology; D008875:Middle Aged; D009955:Ornithine Decarboxylase / Q000378:metabolism
chemical_list: D000975:Antioxidants; D009955:Ornithine Decarboxylase; D001205:Ascorbic Acid